VK2735

Also known as: Viking VK-2735

Status

In trials. Not approved. In phase 3 development with Viking Therapeutics.

What it is

A dual incretin agonist in phase 3 as an injection, with an oral form close behind.

What published research measured

A dual agonist at the GLP-1 and GIP receptors, the same receptor pair as tirzepatide. The VANQUISH-1 and VANQUISH-2 phase 3 trials of the subcutaneous form completed enrolment in 2026, with VANQUISH-2 enrolling around 1,000 adults with type 2 diabetes and obesity or overweight for 78 weeks. A phase 3 program for the oral formulation was expected to begin in late 2026, which if it reads out would make it the first orally available dual GLP-1/GIP agonist.

Source

Bays HE et al. 2026 — Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VE…

Sources

No linked primary source is on file for this entry yet.

Educational use only, never medical advice. No doses.